Clinical Research Informer

Intellia to lay off staff, cut some early research

Bio Pharma Dive

JANUARY 4, 2024

The CRISPR specialist joins some of its genetic medicine peers in trimming staff, announcing an “organizational streamlining” to focus resources on prioritiy drug programs.

Genetics

Genetics Research Medicine Drugs

FDA staff signal support for Biogen ALS drug, but highlight data hurdles

Bio Pharma Dive

MARCH 20, 2023

In documents released Monday, agency staff appeared inclined to approve Biogen’s tofersen, which failed in its main trial. Gathering confirmatory evidence of its benefit could be difficult, however.

Drugs

Drugs Trials

FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks

Bio Pharma Dive

MAY 17, 2023

Staff scientists are concerned Intercept Pharmaceuticals’ drug — which could be the first for non-alcoholic steatohepatitis — may cause liver damage and other health problems, documents show.

Scientist

Scientist Drugs

NextCure to lay off 37% of staff, dial back research plans

Bio Pharma Dive

MARCH 21, 2024

The job cuts at the cancer drug developer will primarily impact manufacturing roles, but will touch on several other parts of the organization, the company said.

Research

Research Manufacturing Development Drugs

Karyopharm cuts staff amid push to broaden use of blood cancer drug

Bio Pharma Dive

AUGUST 2, 2023

The biotech, which has struggled to grow sales of its medicine Xpovio, is laying off 20% of its staff and focusing on late-stage studies in endometrial cancer and myelofibrosis.

Sales

Sales Medicine Drugs

Assembly Bio scraps hepatitis B drug, cuts staff after clinical setback

Bio Pharma Dive

JULY 21, 2022

Two top executives will depart in a restructuring that will reduce the California biotech’s staff by 30% and prioritize a pair of preclinical research programs.

Drugs

Drugs Research

Signal: Apellis sheds staff weight plus R&D in a bid to restructure company

Pharmaceutical Technology

AUGUST 31, 2023

Apellis aims to attain long-term success and focus on star candidate Syfovre by trimming staff and cutting costs.

Boehringer Ingelheim to lay off staff amid biosimilar challenges

Bio Pharma Dive

APRIL 5, 2024

The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

Drugs

Akili exits the prescription DTx market, slashing staff

pharmaphorum

SEPTEMBER 14, 2023

Akili exits the prescription DTx market, slashing staff Phil.Taylor Thu, 14/09/2023 - 17:35 Bookmark this

Marketing

Sangamo sheds staff once again in another retreat

pharmaphorum

NOVEMBER 2, 2023

Sangamo sheds staff once again in another retreat Phil.Taylor Thu, 02/11/2023 - 10:23 Bookmark this

Gilead to lay off staff at cell therapy unit Kite

Bio Pharma Dive

NOVEMBER 29, 2023

The cuts will impact 7% of the cancer drug division’s employees, although about 90 new roles will be created around “areas of growth.”

Drugs

Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced

Fierce Pharma

NOVEMBER 28, 2023

In a letter sent to staff this week that was obtained by Fierce Biotech, Kite Pharma Executive Vice President Cindy Perettie previewed a “refreshed business strategy” that would better align the unit’s strategic priorities.

Addressing Industry Challenges: Staff Turnover

Advarra

DECEMBER 12, 2023

The clinical research industry, like many others, has continued to be challenged by staff turnover in recent years. Staff turnover can greatly impact the quality and progress of an organization’s clinical trials and research projects. The post Addressing Industry Challenges: Staff Turnover appeared first on Advarra.

Clinical Research

Clinical Research Clinical Trials Clinical Trials Research

Pfizer to cut costs, lay off staff on waning demand for COVID products

Bio Pharma Dive

OCTOBER 13, 2023

Sales of Pfizer's antiviral Paxlovid and shot Comirnaty have been slower than it anticipated, while a shift to the commercial market for the antiviral has been delayed.

Production

Production Sales Marketing

Rubius, a once high-flying biotech startup, lays off much of its staff

Bio Pharma Dive

SEPTEMBER 13, 2022

The biotech will reduce staff by 75% and end development of two drugs, the latest setback for a company that was worth nearly $2 billion when it went public in 2018.

Development

Development Drugs

Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears

Fierce Pharma

SEPTEMBER 15, 2023

Lyndra Therapeutics is laying off roughly 23% of its staff, two months after the company swapped out longtime CEO Patricia Hurter, Ph.D., and as a pivotal trial for a long-acting, oral schizophreni | Lyndra Therapeutics is laying off staff two months after a CEO swap and as interim data from a pivotal trial for a schizophrenia drug nears.

Trials

Trials Drugs

Sage sheds staff after narrow Zurzuvae approval

pharmaphorum

SEPTEMBER 1, 2023

Sage sheds staff after narrow Zurzuvae approval Phil.Taylor Fri, 01/09/2023 - 08:31 Bookmark this

BenevolentAI to reduce staff by 30% in business reshuffle

Drug Discovery World

APRIL 25, 2024

Diana Spencer, Senior Digital Content Editor, DDW The post BenevolentAI to reduce staff by 30% in business reshuffle appeared first on Drug Discovery World (DDW).

Licensing

Licensing Licensing Medicine Drugs

FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show

Bio Pharma Dive

SEPTEMBER 25, 2023

Agency scientists flagged numerous issues with Brainstorm’s stem cell treatment ahead of a high-profile Wednesday meeting of expert FDA advisers.

Scientist

FDA staff skeptical of Sarepta’s Duchenne gene therapy, documents show

Bio Pharma Dive

MAY 10, 2023

Sarepta has not provided “unambiguous evidence” its treatment can help patients, agency scientists wrote in documents released ahead of a crucial Friday advisory committee meeting.

Gene Therapy

Gene Therapy Gene Scientist

PTC to lay off more staff following drug setback in Europe

Bio Pharma Dive

SEPTEMBER 29, 2023

The biotech is expanding cuts it announced a few months ago after the EMA decided against renewing a conditional clearance for its drug Translarna.

Drugs

2Seventy CEO Leschly to step down as company cuts staff, spending

Bio Pharma Dive

SEPTEMBER 12, 2023

Citing “near-term headwinds,” the cancer cell therapy developer will lay off 176 employees and pare back some of its research spending.

Development

Development Research

Increasing staff vaccination at nursing homes cuts COVID-19 infections

Medical Xpress

JANUARY 6, 2023

Before the omicron wave, increasing vaccination for staff at U.S. nursing homes was associated with fewer COVID-19 cases and deaths among residents and fewer cases among staff, according to a study published online Dec. 29 in JAMA Network Open.

Nurses

Nurses Vaccination Vaccine Gerontology

Sana reshuffles drug pipeline, becoming latest biotech to cut staff

Bio Pharma Dive

NOVEMBER 30, 2022

The richly funded drugmaker will cut 15% of its workforce, or about 75 employees, as well as stop work on one of its preclinical research programs.

Drugs

Drugs Research

UK’s first digital health training programme for all NHS frontline staff

Pharma Times

MARCH 24, 2022

The platform to build a digital-ready frontline workforce will be available to all NHS and social care staff

uniQure sheds a fifth of its staff and half its R&D

pharmaphorum

OCTOBER 6, 2023

uniQure sheds a fifth of its staff and half its R&D Phil.Taylor Fri, 06/10/2023 - 08:09 Bookmark this

Imara to reduce staff by 83% amid biotech shakeout

Bio Pharma Dive

APRIL 18, 2022

The planned job cuts were announced days after Imara — one of three spinouts from the drug accelerator Cydan Development, stopped development of its top medicine.

Medicine

Medicine Development Drugs

PTC lays off staff, fires CFO as neuromuscular drug study fails

Bio Pharma Dive

MAY 24, 2023

The biotech is giving up on early-stage gene therapy research as part of a restructuring meant to cut costs and redirect resources toward therapies most likely to succeed.

Gene Therapy

Gene Therapy Gene Drugs Research

Fate, two other cell therapy biotechs lay off staff, restructure research

Bio Pharma Dive

JANUARY 6, 2023

The cuts at Fate, Century Therapeutics and TCR2 Therapeutics signal a longer road in the companies’ plans to develop next-generation cell therapies for cancer.

Research

Research Development

Ikena Oncology to lay off 35% of staff

Bio Pharma Dive

JANUARY 19, 2024

The cancer drugmaker is one of about a dozen biotechs that have announced workforce reductions so far in 2024.

Kinnate lays off 70% of staff, reorganizes pipeline

Bio Pharma Dive

SEPTEMBER 19, 2023

The company is restructuring its workforce and discontinuing programs, including its monotherapy combination of its drug exarafenib with Pfizer’s Mektovi.

Drugs

Kronos sheds staff despite positive data for cancer drug

pharmaphorum

NOVEMBER 3, 2023

Kronos sheds staff despite positive data for cancer drug Phil.Taylor Fri, 03/11/2023 - 10:50 Bookmark this

Drugs

Instil Bio Trashes a TIL Therapy, Cuts 60% of Staff

BioSpace

DECEMBER 7, 2022

Instil Bio is discontinuing the development of its unmodified tumor-infiltrating lymphocyte (TIL) therapeutic, ITIL-168, and laying off 60% of its staff.

Development

Employee Retention: How to Get Staff to Stick Around

BioSpace

JULY 13, 2022

Read on to find out how long you can expect your staff to stay and how to keep them. Most employers are well aware of the devastating effects the pandemic has had on employee retention.

Finch to lay off 95% of staff, scrap microbiome drug study

Bio Pharma Dive

JANUARY 24, 2023

The company blamed a range of factors in its decision, including limited funding, slower-than-anticipated trial enrollment and “broader sector trends.”

Drugs

Drugs Trials

Study shows frequent COVID testing of nursing home staff protected residents, saved lives

Medical Xpress

MARCH 22, 2023

A new study, appearing today in the New England Journal of Medicine, shows that nursing homes that conducted staff surveillance testing more regularly during the COVID-19 pandemic experienced significantly lower rates of COVID infections and deaths among residents.

Nurses

Nurses Medicine Gerontology

A once buzzy gene therapy startup lays off staff and shuts down

Bio Pharma Dive

AUGUST 2, 2023

Intergalactic, a developer of non-viral gene therapies built by ex-Biogen executive Michael Ehlers, is folding less than two years after its launch.

Gene Therapy

Gene Therapy Gene Development

BenevolentAI CFO resigns as company lays off staff, restructures

Bio Pharma Dive

MAY 25, 2023

The biotech, one of several AI drug discovery specialists to go public in recent years, is cutting up to 180 jobs and reorganizing its pipeline to conserve cash.

Drugs

Aeglea Cuts Majority of Staff Following Mixed Trial Results

BioSpace

APRIL 12, 2023

Aeglea Cuts Majority of Staff Following Mixed Trial Results 4/12/2023

Trials

Generation bio cuts 40% of staff in blow for non-viral gene therapy sector

Pharmaceutical Technology

NOVEMBER 30, 2023

The move is a strategic response amid challenges faced by the non-viral gene therapy sector, with several startups closing this year.

Gene Therapy

Gene Therapy Gene

Allakos to lay off half of staff, scrap drug after study setback

Bio Pharma Dive

JANUARY 16, 2024

The restructuring adds to a wave of industry layoffs and makes the Californian biotech at least third this year to reduce its workforce by at least 50%.

Drugs

Novavax Cuts 25% of Staff Amid Post-Pandemic Business Challenges

BioSpace

MAY 9, 2023

Novavax Cuts 25% of Staff Amid Post-Pandemic Business Challenges 5/9/2023

Spectrum to lay off R&D staff after FDA drug rejection

Bio Pharma Dive

NOVEMBER 28, 2022

The company will cut its R&D workforce by 75% and discontinue development of its experimental lung cancer drug poziotinib.

Drugs

Drugs Development

Agenus to lay off 25% of staff, trim pipeline in cancer drug push

Bio Pharma Dive

AUGUST 23, 2023

The job cuts are meant to preserve enough cash so the nearly three-decade-old company can potentially pursue its first drug approval next year.

Drugs

Intellia to lay off staff, cut some early research

FDA staff signal support for Biogen ALS drug, but highlight data hurdles

Trending Sources

FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks

NextCure to lay off 37% of staff, dial back research plans

Karyopharm cuts staff amid push to broaden use of blood cancer drug

Assembly Bio scraps hepatitis B drug, cuts staff after clinical setback

Signal: Apellis sheds staff weight plus R&D in a bid to restructure company

Boehringer Ingelheim to lay off staff amid biosimilar challenges

Akili exits the prescription DTx market, slashing staff

Sangamo sheds staff once again in another retreat

Gilead to lay off staff at cell therapy unit Kite

Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced

Addressing Industry Challenges: Staff Turnover

Pfizer to cut costs, lay off staff on waning demand for COVID products

Rubius, a once high-flying biotech startup, lays off much of its staff

Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears

Sage sheds staff after narrow Zurzuvae approval

BenevolentAI to reduce staff by 30% in business reshuffle

FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show

FDA staff skeptical of Sarepta’s Duchenne gene therapy, documents show

PTC to lay off more staff following drug setback in Europe

2Seventy CEO Leschly to step down as company cuts staff, spending

Increasing staff vaccination at nursing homes cuts COVID-19 infections

Sana reshuffles drug pipeline, becoming latest biotech to cut staff

UK’s first digital health training programme for all NHS frontline staff

uniQure sheds a fifth of its staff and half its R&D

Imara to reduce staff by 83% amid biotech shakeout

PTC lays off staff, fires CFO as neuromuscular drug study fails

Fate, two other cell therapy biotechs lay off staff, restructure research

Ikena Oncology to lay off 35% of staff

Kinnate lays off 70% of staff, reorganizes pipeline

Kronos sheds staff despite positive data for cancer drug

Instil Bio Trashes a TIL Therapy, Cuts 60% of Staff

Employee Retention: How to Get Staff to Stick Around

Finch to lay off 95% of staff, scrap microbiome drug study

Study shows frequent COVID testing of nursing home staff protected residents, saved lives

A once buzzy gene therapy startup lays off staff and shuts down

BenevolentAI CFO resigns as company lays off staff, restructures

Aeglea Cuts Majority of Staff Following Mixed Trial Results

Generation bio cuts 40% of staff in blow for non-viral gene therapy sector

Allakos to lay off half of staff, scrap drug after study setback

Novavax Cuts 25% of Staff Amid Post-Pandemic Business Challenges

Spectrum to lay off R&D staff after FDA drug rejection

Agenus to lay off 25% of staff, trim pipeline in cancer drug push

Stay Connected